The main molecular basis of Essential Thrombocytemia and hereditary thrombocytosis are acquired and germline activating mutations affecting the thrombopoietin signaling axis. We Moreover, these mutants were less sensitive to JAK2 and HSP90 inhibitors than JAK2 V617F. Our results suggest that the mutations in the kinase domain of JAK2 may confer a weak activation of signaling specifically dependent on MPL, while inducing a decreased sensitivity to clinically available JAK2 inhibitors.
Introduction
Thrombocytosis are rare entities characterized by an abnormal proliferation of the megakaryocytic lineage resulting in overproduction of platelets (>450 x 10 9 /L in adults). The overproduction of platelets is related to the activation of the thrombopoietin (TPO) / TPO receptor (MPL) axis that signals through several pathways that include Janus kinase 2 (JAK2)/STAT1-3-5, PI3K/AKT, and MAPK. 1, 2 Familial thrombocytosis are heterogeneous disorders that can be subdivided into true myeloproliferative neoplasms (MPNs) transmitted by autosomal inheritance with incomplete penetrance, and hereditary thrombocytosis with an autosomal dominant pattern and an early onset (complete penetrance) of the hematological abnormalities. 3, 4 The latter are considered as non-malignant diseases due to the polyclonal nature of hematopoiesis.
To date, germline mutations that have been identified in familial thrombocytosis all affect genes involved in TPO/MPL signaling. The genes targeted by germline mutations in familial thrombocytosis are often the same than sporadic mutations in MPNs, but the mutations disrupt different residues in the proteins. They include MPL S505N and MPL P106L, leading to the constitutive activation of the receptor and to a presumptive defect of TPO binding, respectively. [5] [6] [7] An MPL W515R mutation, which is rare in sporadic MPNs compared to MPL W515L or W515K, has also recently been identified in familial thrombocytosis. 8 Likewise, two germline mutations, JAK2 V617I (different from the V617F substitution classically found in 60% of sporadic Essential Thrombocythemia (ETs), and JAK2 R564Q (never observed in sporadic MPNs) have been reported. [9] [10] [11] Several mutations in the TPO gene that lead to increased TPO translation, have also been described in families with a thrombocytosis. [12] [13] [14] [15] Here, we report two families with hereditary thrombocytosis carrying so far unidentified heterozygous germline mutations in JAK2.
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Methods

Materials.
Human recombinant EPO and IL-3 were generous gifts from Amgen (Neuilly, France). SCF was from Biovitrum AB (Stockholm, Sweden) and recombinant TPO a generous gift from Kirin (Tokyo, Japan). Restriction enzymes were purchased from Fermentas (St Leon-Rot, Germany).
Patients and cell purification.
Pedigrees of hereditary thrombocytosis registered in the National collection of MPNs (DC 2009-957) were analyzed. All participants gave their written informed consent. Clinical and biological annotations were recorded in an Access database approved by the French computer commission (CNIL #815419). This study was conducted in accordance with the Declaration of Helsinki. Thrombocytosis was defined by a platelet count above 450 x 10 9 /L in patients who had no evidence for reactive thrombocytosis and no WHO criteria for ET. 16 Peripheral blood from patients was collected in sterile citrated tubes. Platelet-rich plasma (PRP) was obtained by centrifugation at 180 x g for 15 min at 20°C. PRP was mixed with acid citrate dextrose at 9:1 ratio and centrifuged at 1,500 x g for 15 min at 20°C. Platelet pellet was carefully resuspended in PBS with 0.1% EDTA. Blood mononuclear cells (BMC) were plated in 6-well plates for 1 hr to remove monocytes and then seeded in semi-solid cultures or were used to sort CD34 + and CD3 + cells by flow cytometry.
Quantification of clonogenic progenitors in semi-solid cultures.
BMC were plated in methylcellulose and erythroid (BFU-E) and granulo-monocytic (CFU-GM) progenitors were counted 14 days later. BMC were evaluated in serum-free fibrin clot assays to quantify megakaryocytic progenitor (CFU-MK)-derived colonies at day 10 by an
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Amplification of the 25 exons and intron-exon boundaries of JAK2 (NM_004972.3) was performed in the probands on genomic DNA extracted from BMC. Purified PCR products were sequenced in both directions using the BigDye Terminator chemistry (Life Technologies, Saint-Aubin, France) on an ABI3730 Genetic Analyser.
DNA manipulations, production of retroviruses.
The 2265T>A (S755R), 2600G>A (R867Q) and 2813G>A (R938Q) point mutations were introduced into the MIGR1-human JAK2 WT-IRES-GFP plasmid by the QuikChange sitedirected mutagenesis method using the PfuUltra high-fidelity DNA polymerase (Stratagene Amsterdam, The Netherlands). Full-length JAK2 mutant cDNAs were verified by sequencing.
Vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped viral particles were produced into 293EBNA cells.
Cell lines.
The murine pro-B Ba/F3 cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS) (Stem Cell Technologies, Grenoble, France) and 5% WEHI-conditioned medium as a source of murine IL-3. Ba/F3 cells were retrovirally transduced with MIGR1-IRES-CD4 to stably express the human receptor of EPO (EPOR) or TPO (MPL) harboring a N-terminal FLAG tag and maintained in presence of 1 U/mL EPO and 5% WEHI, respectively. Ba/F3-EPOR and Ba/F3-MPL cell lines expressing the various JAK2 mutants were generated after transduction and subsequent GFP + cell sorting by flow cytometry (MoFlo, Beckman-Coulter, Villepinte, France).
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Proliferation assays.
The premixed WST-1 cell proliferation assay system was carried out according to manufactor's instructions (Takara Bio Europe, Clontech, Saint-Germain-en-Laye, France).
Experiments were done in triplicate. For inhibitor treatments, values were transformed to percent inhibition relative to vehicle (DMSO)-treated cells and sigmoidal curves were fitted according to nonlinear regression analysis of the data using GraphPad PRISM software to calculate IC 50 . Dose-response curves to EPO and TPO were expressed as percent of viability of the maximal response.
Western blot analysis and co-immunoprecipitation.
Signaling studies were performed on platelets and Ba/F3 cell lines by Western blot analysis using polyclonal antibodies against the phosphorylated forms of JAK2 (Tyr 1007/ 
Cell-surface expression of FLAG-tagged MPL.
Expression of MPL at the surface of Ba/F3 cells was examined by flow cytometry with 10 μg/mL monoclonal anti-FLAG M2 antibody (Sigma) followed with 1:400-diluted PE- Transcriptional activation of STAT5, STAT3 and STAT1 was analyzed in γ2A JAK2-deficient cells using the dual pGRR5 firefly luciferase reporter (responding to STATs) and pRL-TK-driven renilla luciferase system. γ2A cells were transiently transfected using Lipofectamine reagent with cDNAs coding for JAK2 (or mutants thereof), MPL and either STAT5, STAT3 or STAT1 as described. 19 A Perkin-Elmer Victor X Light analyzer was used for detecting luminescence in cell lysates.
Modeling of mutation effects in JAK2 JH2 and JH1. 
Results
Identification of new germline JAK2 mutations.
We performed a genome-wide SNP analysis of a large pedigree (Family 1) with seven affected members (individuals 1 to 7) showing only JAK2 V617F-negative thrombocytosis ( Figure 1A) . We genotyped the affected individuals using the Affymetrix 6.0 SNP-array (906,622 SNPs) and determined nine chromosomal regions with SNP alleles shared by all of them. One was located on chromosome 9 and encompassed the JAK2 locus (Supplemental Table S1 ). Sequencing of the entire JAK2 gene identified two heterozygous JAK2 mutations, i.e. c.2265T>A (S755R) and c.2813G>A (R938Q). Segregation analysis showed that both mutations were located on the same allele ( Figure 1A ). Subsequently, we analyzed five other families characterized by isolated elevated platelet counts ranging from 470 to 1,900 x 10 9 /L, the absence of JAK2 V617F, an age at onset <40 years in at least one affected case and a family history compatible with an autosomal dominant inheritance. They were sequenced for JAK2 and a new single heterozygous JAK2 mutation c.2600G>A (R867Q) was found in Supplemental Table S2 .
The identified mutations are novel JAK2 missense mutations that have not been reported in genomic databases. The S755R mutation is located in the pseudokinase domain (JH2)
whereas R867Q and R938Q mutations are situated in the kinase domain (JH1) of the protein (Figure 2A ). These mutations affect amino acids that are highly conserved across species and
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From in silico analysis of the potential impact of these substitutions predicted a pathogenic effect on JAK2 function (Supplemental Table S3 ). More specifically, the R867Q mutation in JH1 was predicted to abolish a salt bridge (between R867 and D869), which is present in the inactive JH1, and is lost upon activation. 20 Thus, the R867Q mutation would result in an active state in the region around β -sheets 2 and 3 ( Figure 2B ). The S755R mutation was predicted to interfere with another important salt bridge (between D635 from α-helix D and K752 in the region linking α-helix D to α -helix G) with the bulky positive R755 triggering a steric clash ( Figure 2B ). 21 The loss of this salt bridge may destabilize the network of α-helices at the Cterminus of JH2, by pushing away helix G. This network of helices has previously been shown to exert inhibitory effects on JH1. 22 The R938Q is located in a sensitive region of the JH1, not far from the ATP loop and substrate access site ( Figure 2B ).
To determine the clonality of hematopoieisis of these JAK2 mutated patients, we carried out methylation-sensitive PCR assays using the HUMARA and PCSK1N loci on granulocytes and CD3 + cells of three affected women (subjects 3 and 7 of Family 1 and subject 3 of Family 2). 23 Results were in favor of a polyclonal hematopoiesis as opposed to a JAK2 V617F-positive patient with Polycythemia Vera who displayed a complete X-inactivation in agreement with a clonal hematopoiesis (Supplemental Table S4 ).
Finally, we verified that the TPO/MPL axis controlling platelet production was not affected besides the mutations of JAK2, by sequencing MPL and assessing TPO levels in plasma for these two families. No mutation was identified in MPL for patient 2 of Family 1 and patient 3 of Family 2, and TPO levels were inside the normal range (<30 pg/mL) (Supplemental Table   S2 ).
JAK2 R867Q and JAK2 S755R/R938Q are gain-of-function mutations that induce spontaneous growth and constitutive signaling of MPL-expressing cells.
We modeled the JAK2 mutations in Ba/F3 cells lines expressing either MPL (Ba/F3-MPL) or
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From EPOR (Ba/F3-EPOR). Ba/F3-MPL and -EPOR expressing JAK2 V617F or JAK2 WT were used as controls. We measured cellular proliferation in response to cytokines using MTT-like assays. None of the JAK2 mutants, except JAK2 V617F, conferred hypersensitivity to EPO to the Ba/F3-EPOR cell line ( Figure 3A ). In contrast, the Ba/F3-MPL cells expressing either of the JAK2 mutants, except for JAK2 S755R, could be maintained in cytokine-deprived condition (>3 weeks). Independency to TPO was confirmed using a MTT-like assay ( Figure   3B ). TPO induced a sigmoidal dose-response curve in Ba/F3-MPL cell line ( Figure 3B , "endogenous"). As previously described for JAK2 WT and JAK2 V617F 24, 25 For personal use only. on October 24, 2017. by guest www.bloodjournal.org From JAK2 mutants induced constitutive signaling of the same pathways. Noticeably, in the presence of R867Q and S755R/R938Q JAK2 mutants, we detected a spontaneous activation of STAT1. JAK2 S755R alone did not induce any constitutive phosphorylation besides a weak activation of STAT5 ( Figure 4B ). This last result implies that the S755R mutation compared to the R938Q mutation might play a lesser role in the constitutive signaling of JAK2 S755R/R938Q.
We then co-transfected JAK2 V617F, R867Q or S755R/R938Q mutant in JAK2-deficient γ2A cells in the presence of a similar amount of JAK2 WT to mimic the heterozygous state of the mutations found in patients. The effect of these mutants combined with MPL on STAT1, STAT3 or STAT5 activation was measured by luciferase assays. Figure 4C shows that mutants of JAK2 induced constitutive signaling primarily via STAT1 and, to a lesser extent via STAT3 in MPL-expressing cells and under conditions of heterozygosity. Of note, JAK2 S755R had no effect on basal STAT activation (Supplemental Figure S1) . Activation of the STATs was dependent on MPL (Supplemental Figure S2A ). In addition, we used a battery of six coiled-coil MPL dimeric fusion proteins, with different orientations. 26 The two new JAK2 mutants were consistently weaker than JAK2 V617F and mostly induced STAT-dependent signaling only in the presence of active or partially active MPL dimeric orientations, and were less active in the presence of cc-MPL-II (Supplemental Figure S2B ).
Taken together, these results show that the constitutive signaling of JAK2 R867Q, R938Q and S755R/R938Q is dependent on the presence of MPL and leads to growth-factor independency and hypersensitivity to TPO.
JAK2 mutants are less sensitive than JAK2 V617F to classical JAK2 inhibitors and a HSP90 inhibitor in Ba/F3 cell lines.
Randomly generated point mutations in the kinase domain of JAK2 V617F have been shown to be resistant to JAK2 inhibitors while still sensitive to inhibition of HSP90, a chaperone for
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to a PI3K inhibitor (LY-294002) ( Figure 5C ), suggesting that the three JAK2 mutants (R867Q, S755R/R938Q and V617F) require downstream PI3K for Ba/F3-MPL cell proliferation. However, they were less sensitive than JAK2 V617F to a HSP90 inhibitor (AUY922), even at high doses ( Figure 5D ). Accordingly, HSP90 co-immunoprecipitated to a greater extent with JAK2 mutants (R867Q, S755R/R938Q) than with JAK2 V617F and WT ( Figure 5F ).
Altogether, these results show that the new JAK2 mutants are less sensitive than JAK2 V617F
to both JAK2 and HSP90 inhibitors.
Effects of JAK2 mutants on MPL stability and MPL cell-surface localization.
To understand the properties of these JAK2 mutants, we assessed their stability. We treated Figure 6A ). JAK2 S755R/R938Q mutant was twofold more stable than JAK2 WT, whereas JAK2 V617F was two-fold less stable than JAK2 WT. JAK2 R867Q was found as stable as JAK2 WT. Moreover, JAK2 S755R/R938Q significantly increased the stability of cell-surface MPL compared to the other JAK2.
We next assessed the level of cell-surface MPL in the presence of the JAK2 mutants by flow cytometry using an anti-FLAG antibody. As previously described 25 , overexpression of JAK2
WT led to increased MPL cell-surface expression, whereas JAK2 V617F induced its decrease.
In good agreement with their stabilities, JAK2 S755R/R938Q allowed a 2-fold augmentation of MPL cell-surface expression while JAK2 R867Q behaved similarly as JAK2 WT ( Figures   6B and C) . Thus, the half-life of the JAK2 mutants directly correlated with their ability to promote cell surface localization of MPL.
In patients, JAK2 mutants specifically act on the megakaryocytic lineage. As expected from Ba/F3-MPL cell lines, we observed a weak spontaneous phosphorylation of Figure S3 ). Moreover TPO-induced phosphorylation of STAT3 and STAT5 was reduced in the JAK2 R867Q patients compared to the control, while STAT1 phosphorylation was stimulated by TPO equally well in patients and in the control ( Figure 7K ).
Altogether, these results show that JAK2 R867Q and JAK2 S755R/R938Q both stimulate moderately but specifically MK proliferation, which correlates with STAT1-mediated signaling.
For
Discussion
In this study, we identified two families with hereditary thrombocytosis carrying three so far unidentified heterozygous JAK2 germline mutations in the kinase and pseudokinase domains. One family displayed a single point mutation in the JAK2 kinase domain (R867Q) and the other one two mutations in the same JAK2 allele affecting the pseudokinase (S755R) and the kinase (R938Q) domains. This is the first report of inherited mutations in the kinase domain of JAK2 associated with a thrombocytosis phenotype while JAK2 R867Q was initially identified in a pediatric acute lymphoblastic leukemia. 29 Two novel germline mutations in the pseudokinase domain of JAK2 (V617I and R564Q) have recently been observed in hereditary thrombocytosis. 9, 11 Thrombotic complications appear to be rare in the patients of these two families, suggesting that familial thrombocytosis related to these molecular variants could be underestimated. mutants have a significantly weaker constitutive activity than JAK2 V617F. This is reminiscent of JAK2 V617I mutant shown to be weaker than JAK2 V617F on the growth of cytokine independent progenitors. 10, 11, 19 Signaling induced by JAK2 S755R/R938Q may result from the unusual long half-life of this mutant correlating with MPL cell-surface expression and stability. One major difference between MPL and EPOR is the extended
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From stability of the mature cell-surface MPL while EPOR is highly unstable. 30 We suppose that the high stability of both MPL and the new JAK2 S755R/R938Q mutant induces a weak but persistent signal that will be sufficient to promote thrombocytosis, but not erythrocytosis. On the other hand, our results suggest a different mechanism for the constitutive activation of JAK2 R867Q. Significantly increased levels of autophosphorylation of this JAK2 mutant
were detected compared to the other JAK2 mutants, possibly indicating an impaired regulation by phosphatases.
Interestingly, detailed studies in γ2A cells where we examined the ability of JAK2 mutants to activate STAT1, STAT3 and STAT5 via MPL in heterozygous situations showed that they essentially activate STAT1. These results are in line with the observation that these mutations specifically activate STAT1 in platelets from patients and in Ba/F3-MPL cells. A previous study showed that JAK2 V617F-induced high phosphorylation level of STAT1 is associated with an ET-like phenotype without change in the number of red cells. 31 In the Ba/F3-MPL cell model, overexpression of JAK2 V617F mimics the homozygous state of the mutation, characteristic of Polycythemia Vera and did not induce spontaneous STAT1
phosphorylation. In contrast, the MPL-expressing γ2A cell model where JAK2 V617F and JAK2 WT were cotransfected, reproduces the heterozygous JAK2 V617F configuration found in ET patients, and JAK2 V617F stimulated the TPO-independent phosphorylation of STAT1.
Finally, we studied the respective functions of the individual JAK2 S755R and JAK2 R938Q mutants in Ba/F3 cells. We found that JAK2 R938Q was the key activating mutation since it induced constitutive signaling and the growth of Ba/F3-MPL cells like JAK2 S755R/R938Q. In contrast, JAK2 S755R activity was comparable to JAK2 WT except at high doses of TPO. This subtle difference might be important for the double mutant to escape a senescence-like phenotype, since JAK2 WT was shown to induce senescence and antiproliferative effects at high levels of TPO. 24, 25 Presumably, the heterozygous expression of JAK2 R938Q in patients might not be sufficient to induce a thrombocytosis, while R938Q
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The R867Q and S755R/R938Q mutations conferred resistance to several JAK2 enzymatic inhibitors such as Ruxolitinib, TG101348, CYT387 and AZ960. In particular, Ruxolitinib and CYT387 failed to induce a complete inhibition of Ba/F3-MPL cell growth at high doses. It was reported that synthetic mutants of the kinase domain of JAK2 V617F, generated by random mutagenesis, were less sensitive to these inhibitors. 27, 28 The resistance of JAK2 R867Q and S755R/R938Q mutants to type I ATP-competitive inhibitors of JAK2 is likely to reflect allosteric effects on the ATP-binding pocket induced by the disruption of kinase domain and pseudokinase domain salt bridges (R867-D869 and D635-K752).
Furthermore, R867Q and R938Q mutations are in proximity of residues that were previously shown to generate resistant mutants (E864K and Y931C), thus indicating that the allosteric effects on ATP binding pocket can be induced by several mutations in those regions. 27, 28, 32 Recently, some studies have focused their interest on HSP90, an essential chaperone for JAK2 stability. Inhibition of HSP90 promotes the degradation of both JAK2 WT and JAK2 V617F. Weigert et al. reported that their synthetic mutants of JAK2, which were resistant to JAK2 inhibitors, remained sensitive to HSP90 inhibition. 28 In contrast, our data showed that JAK2 R867Q-and JAK2 S755R/R938Q-expressing Ba/F3-MPL cells were also less sensitive to the HSP90 inhibitor AUY922 than cells harboring JAK2 V617F. Resistance to AUY922 is probably due to a more stable interaction between HSP90 and JAK2 S755R/R938Q or R867Q. JAK2 V617F was the least stable mutant and also the best target for both ATPcompetitive JAK2 inhibitors and HSP90 inhibitors. These natural mutants of JAK2 that are less sensitive to the current JAK2 and HSP90 inhibitors could be used as models to screen new small molecules that could benefit to MPN patients. 
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